

Gregory A Yanik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9014368/publications.pdf>

Version: 2024-02-01

83
papers

3,187
citations

147801

31
h-index

161849

54
g-index

86
all docs

86
docs citations

86
times ranked

4091
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1054-1060.	1.6	228
2	Phase I Dose Escalation of Iodine-131-Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 500-506.	1.6	170
3	Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group. <i>Journal of Nuclear Medicine</i> , 2013, 54, 541-548.	5.0	169
4	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	5.0	166
5	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	1.4	140
6	Pilot Study of Iodine-131-Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2142-2149.	1.6	132
7	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 87-95.	10.7	113
8	Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children. <i>Clinical Infectious Diseases</i> , 2019, 68, 1847-1855.	5.8	112
9	Iodine-131-Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1020-1025.	1.6	110
10	Î±1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018, 131, 1372-1379.	1.4	81
11	131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 673-681.	2.0	79
12	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 858-864.	2.0	78
13	Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. <i>Blood</i> , 2015, 125, 2435-2444.	1.4	73
14	Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. <i>Circulation</i> , 2020, 142, 1687-1690.	1.6	70
15	Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 895-895.	1.4	70
16	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 66-81.	5.0	70
17	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1710-1718.	10.7	65
18	Inhibition of Neutrophil Extracellular Trap Formation after Stem Cell Transplant by Prostaglandin E ₂ . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 186-197.	5.6	64

#	ARTICLE	IF	CITATIONS
19	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 2715-2721.	7.0	62
20	Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 221-221.	1.4	62
21	131I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 184-202.	4.6	58
22	The Lung as a Target Organ of Graft-Versus-Host Disease. <i>Seminars in Hematology</i> , 2006, 43, 42-52.	3.4	57
23	Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 292-305.	6.4	54
24	Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. <i>Journal of Nuclear Medicine</i> , 2018, 59, 502-508.	5.0	52
25	Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG). <i>European Journal of Cancer</i> , 2015, 51, 2465-2472.	2.8	50
26	An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26758.	1.5	50
27	Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1044-1054.	2.0	48
28	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	1.4	48
29	Lung Dysbiosis, Inflammation, and Injury in Hematopoietic Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1312-1321.	5.6	42
30	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
31	Review at a multidisciplinary tumor board impacts critical management decisions of pediatric patients with cancer. <i>Pediatric Blood and Cancer</i> , 2017, 64, 254-258.	1.5	35
32	Theranostics: Evolution of the Radiopharmaceutical Meta-Iodobenzylguanidine in Endocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 171-184.	4.6	34
33	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26545.	1.5	30
34	First-Onset Herpesviral Infection and Lung Injury in Allogeneic Hematopoietic Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 63-74.	5.6	30
35	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. <i>Blood Advances</i> , 2021, 5, 593-601.	5.2	28
36	Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry. <i>Blood</i> , 2019, 134, 2619-2619.	1.4	28

#	ARTICLE	IF	CITATIONS
37	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	5.2	27
38	Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. <i>Annals of the American Thoracic Society</i> , 2021, 18, 381-394.	3.2	26
39	Procedure-related complications and adverse events associated with pediatric autologous peripheral blood stem cell collection. <i>Journal of Clinical Apheresis</i> , 2017, 32, 35-48.	1.3	24
40	Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1426-1434.	2.0	20
41	Transforming growth factor- β 2 induces microRNA-29b to promote murine alveolar macrophage dysfunction after bone marrow transplantation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L86-L95.	2.9	20
42	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 137, 983-993.	1.4	20
43	Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 474-481.	6.4	19
44	Respiratory Tract Colonization by <i>Candida</i> Species Portends Worse Outcomes in Immunocompromised Patients. <i>Clinical Pulmonary Medicine</i> , 2018, 25, 197-201.	0.3	18
45	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1651-1656.	2.0	18
46	Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 531-537.	2.4	17
47	A safety and feasibility trial of ^{131}I -MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29117.	1.5	17
48	Management of noninfectious lung injury following hematopoietic cell transplantation. <i>Current Opinion in Oncology</i> , 2013, 25, 187-194.	2.4	16
49	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	7.2	16
50	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 490.e1-490.e8.	1.2	14
51	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 54-60.	2.0	12
52	Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1551-1551.	1.4	12
53	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
54	Response to Maccio et al, "Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrinogenase have a role in the early phases of coagulation disorders?" <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3111-3113.	3.8	10

#	ARTICLE	IF	CITATIONS
55	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7.	1.2	10
56	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 955-964.	2.0	7
57	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 423-433.	3.4	6
58	A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10003-10003.	1.6	6
59	Survival Following Etanercept Therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 354-354.	1.4	5
60	Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27417.	1.5	4
61	An owner's manual for CD19 CAR-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2021, 50, 100848.	5.7	4
62	Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients. <i>Blood</i> , 2018, 132, 899-899.	1.4	4
63	Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802. <i>Blood</i> , 2017, 130, 72-72.	1.4	3
64	Tacrolimus Versus Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Pediatric Patients Undergoing Matched Unrelated Donor Hematopoietic Stem Cell Transplants. <i>A Pediatric Blood and Marrow Transplant Consortium Study...</i> <i>Blood</i> , 2006, 108, 2883-2883.	1.4	2
65	Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10523-10523.	1.6	2
66	Development and validation of a pediatric disease risk index for allogeneic hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7503-7503.	1.6	2
67	Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome. <i>Pediatric Blood and Cancer</i> , 2016, 63, 164-167.	1.5	1
68	Early Post-Transplant Viral Infections and the Incidence of Acute and Chronic Noninfectious Pulmonary Complications Following Hematopoietic Stem Cell Transplantation (HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1-2.	2.0	1
69	Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Blood</i> , 2015, 126, 1907-1907.	1.4	1
70	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509.	1.4	1
71	Changes in TNFR1 Levels in the First Week Post-Myeloablative HSCT Correlate with Severity and Incidence of GVHD and 1y TRM.. <i>Blood</i> , 2006, 108, 37-37.	1.4	1
72	Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10029-10029.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Validation of postinduction Curie scores in high-risk neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 10031-10031.	1.6	1
74	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. Blood, 2020, 136, 6-8.	1.4	1
75	The Use of Laparoscopic Liver Biopsies in Pediatric Patients with Hepatic Dysfunction Following Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 1147-1147.	1.4	0
76	Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.. Blood, 2007, 110, 39-39.	1.4	0
77	Phase I study of proteasome inhibitor bortezomib in combination with irinotecan in patients with relapsed/refractory neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 10051-10051.	1.6	0
78	Vesicular monoamine transporter protein expression in neuroblastoma: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2015, 33, 10043-10043.	1.6	0
79	Clinical, biologic, and outcome differences according to MIBC avidity in children with neuroblastoma: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10526-10526.	1.6	0
80	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. Blood, 2016, 128, 510-510.	1.4	0
81	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. Blood, 2018, 132, 356-356.	1.4	0
82	Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. Blood, 2021, 138, 3900-3900.	1.4	0
83	Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome. Blood, 2021, 138, 3237-3237.	1.4	0